ArticleJournal of computer-aided molecular design2026
Computational framework to quantify synergistic ligand activity in insulin secretion and resistance pathways in type 2 diabetes.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) involves dysregulation of both insulin secretion and insulin resistance pathways. However, current therapies often target only one pathway, leading to limited effectiveness. We aimed to develop a computational framework to quantify synergistic ligand activity across both pathways, providing a foundation for multi-target therapeutic strategies. We built a synergy assessment framework targeting six key proteins: glucagon-like peptide-1 receptor (GLP1R) and kinesin family member 11 (KIF11) in the insulin secretion pathway; and insulin-like growth factor 1 receptor (IGF1R), insulin receptor (INSR), peroxisome proliferator-activated receptor gamma (PPARG), and fibroblast growth factor receptor 1 (FGFR1) in the insulin resistance pathway. Ligand data were compiled from ChEMBL, PubChem, and ZINC databases, with bioactivity standardized as pIC50 values. Pathway activities were quantified as Secretion Pathway Activity (Asec) and Resistance Pathway Activity (Ares). Synergistic effects were evaluated using expected effect (Eexp), synergy factor (SF = 0.5 × Asec × Ares), actual effect (Eact = min (1.0, Eexp + SF)), and net synergy value (Δsyn = Eact − Eexp). Molecular docking validation showed high-synergy compounds exhibited favorable binding energies (< − 7 kcal/mol), with docking scores correlating strongly with experimental pIC50 values (r > 0.7). Notably, CID_45271263 demonstrated potent binding affinity (< − 10 kcal/mol) for both GLP1R and KIF11. Network analysis identified INSR as a critical hub connecting both pathways. High-synergy ligands preferentially engaged both pathways simultaneously, with significant inter-pathway correlations observed between GLP1R-PPARG (r = 0.86) and KIF11-FGFR1 (r = 0.93). Three-dimensional modeling revealed non-linear synergistic surfaces with distinct high-efficacy zones (Δsyn > 0.12). In conclusion, this validated computational framework enables the systematic identification and design of multi-target drugs with enhanced synergistic effects, thereby improving the therapeutic efficacy of T2DM.
Indexed as
Identifiers
41952002What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.